Dr Myra Hardy

Dr Myra Hardy

Details

Role Postdoctoral Researcher
Dr Myra Hardy is a Paediatric Infectious Diseases Physician with a strong interest in global health that stems from her early research evaluating the burden of rheumatic heart disease in school children in Tonga. During her paediatric training, she has worked in Melbourne, Darwin, Solomon Islands and Canada. She has recently completed her PhD based in Fiji investigating the safety and efficacy of Ivermectin, Diethylcarbamazine, and Albendazole for lymphatic filariasis control and the non-inferiority of one-dose versus two-dose Ivermectin-based Mass drug administration (MDA) for the community control of scabies.

Myra is currently a postdoctoral researcher in the Tropical Diseases group, Infection, Immunity and Global Health research area at Murdoch Children’s Research Institute. Her ongoing research focuses on the acceptability of ivermectin, diethylcarbamazine and albendazole, the impact on soil-transmitted helminths and further evaluation of the efficacy of treatments for lymphatic filariasis in Fiji.
Dr Myra Hardy is a Paediatric Infectious Diseases Physician with a strong interest in global health that stems from her early research evaluating the burden of rheumatic heart disease in school children in Tonga. During her paediatric training, she...
Dr Myra Hardy is a Paediatric Infectious Diseases Physician with a strong interest in global health that stems from her early research evaluating the burden of rheumatic heart disease in school children in Tonga. During her paediatric training, she has worked in Melbourne, Darwin, Solomon Islands and Canada. She has recently completed her PhD based in Fiji investigating the safety and efficacy of Ivermectin, Diethylcarbamazine, and Albendazole for lymphatic filariasis control and the non-inferiority of one-dose versus two-dose Ivermectin-based Mass drug administration (MDA) for the community control of scabies.

Myra is currently a postdoctoral researcher in the Tropical Diseases group, Infection, Immunity and Global Health research area at Murdoch Children’s Research Institute. Her ongoing research focuses on the acceptability of ivermectin, diethylcarbamazine and albendazole, the impact on soil-transmitted helminths and further evaluation of the efficacy of treatments for lymphatic filariasis in Fiji.

Top Publications

  • Weil, GJ, Bogus, J, Christian, M, Dubray, C, Djuardi, Y, Fischer, PU, Goss, CW, Hardy, M, Jambulingam, P, King, CL, et al. The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study. PLOS Medicine 16(6) : e1002839 2024
    view publication
  • Goss, CW, O’Brian, K, Dubray, C, Fischer, PU, Hardy, M, Jambulingam, P, King, CL, Laman, M, Lemoine, JF, Robinson, LJ, et al. Dosing pole recommendations for lymphatic filariasis elimination: A height-weight quantile regression modeling approach. PLOS Neglected Tropical Diseases 13(7) : e0007541 2024
    view publication
  • Hardy, M, Samuela, J, Kama, M, Tuicakau, M, Romani, L, Whitfeld, MJ, King, CL, Weil, GJ, Grobler, AC, Robinson, LJ, et al. The safety of combined triple drug therapy with ivermectin, diethylcarbamazine and albendazole in the neglected tropical diseases co-endemic setting of Fiji: A cluster randomised trial. PLOS Neglected Tropical Diseases 14(3) : e0008106 2024
    view publication
  • Krentel, A, Basker, N, de Rochars, MB, Bogus, J, Dilliott, D, Direny, AN, Dubray, C, Fischer, PU, Ga, AL, Goss, CW, et al. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis. PLOS Neglected Tropical Diseases 15(3) : e0009002 2024
    view publication
  • Azzopardi, KI, Hardy, M, Baker, C, Bonnici, R, Llewellyn, S, McCarthy, JS, Traub, RJ, Steer, AC. Detection of six soil-transmitted helminths in human stool by qPCR- a systematic workflow. PLOS ONE 16(9) : e0258039 2024
    view publication

Page 1 of 3